JAK-STAT signaling activated by Abl oncogenes - PubMed (original) (raw)
Review
. 2000 May 15;19(21):2523-31.
doi: 10.1038/sj.onc.1203484.
Affiliations
- PMID: 10851051
- DOI: 10.1038/sj.onc.1203484
Review
JAK-STAT signaling activated by Abl oncogenes
N N Danial et al. Oncogene. 2000.
Abstract
The Abl oncoproteins v-Abl and BCR-Abl can activate member of the signal transducers and activators of transcription (STAT) family of signaling proteins. The mechanisms by which these oncoproteins activate STATs appear to differ. In cells transformed by v-Abl, Janus kinase (JAK) tyrosine kinases are constitutively activated. In these cells, the v-Abl oncoprotein and the JAK kinases physically associate. Mapping of the JAK interaction domain in v-Abl demonstrates that amino acids within the carboxyl terminal region of v-Abl bind JAKs through a direct interaction. A mutant of v-Abl lacking this region does not bind or activate JAK 1 in vivo, fails to activate STAT proteins, does not induce cellular proliferation, and is less efficient in cellular transformation. Kinase inactive mutants of JAK 1 inhibit the ability of v-Abl to activate STATs, to induce cytokine-independent proliferation, and to transform bone marrow cells. Interestingly, these effects correlate with defects in the activation of several pathways by v-Abl including Akt, PI3-kinase, STATs, and Ras. These data suggest that Jak kinases may play an important role in v-Abl induced transformation. Oncogene (2000).
Similar articles
- Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation.
Danial NN, Losman JA, Lu T, Yip N, Krishnan K, Krolewski J, Goff SP, Wang JY, Rothman PB. Danial NN, et al. Mol Cell Biol. 1998 Nov;18(11):6795-804. doi: 10.1128/MCB.18.11.6795. Mol Cell Biol. 1998. PMID: 9774693 Free PMC article. - v-Abl signaling disrupts SOCS-1 function in transformed pre-B cells.
Limnander A, Danial NN, Rothman PB. Limnander A, et al. Mol Cell. 2004 Aug 13;15(3):329-41. doi: 10.1016/j.molcel.2004.06.041. Mol Cell. 2004. PMID: 15304214 - IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled.
Reddy EP, Korapati A, Chaturvedi P, Rane S. Reddy EP, et al. Oncogene. 2000 May 15;19(21):2532-47. doi: 10.1038/sj.onc.1203594. Oncogene. 2000. PMID: 10851052 Review. - Abl oncogene bypasses normal regulation of Jak/STAT activation.
Limnander A, Rothman PB. Limnander A, et al. Cell Cycle. 2004 Dec;3(12):1486-8. doi: 10.4161/cc.3.12.1297. Epub 2004 Dec 12. Cell Cycle. 2004. PMID: 15611644 Review.
Cited by
- Phosphatidic Acid Increases Epidermal Growth Factor Receptor Expression by Stabilizing mRNA Decay and by Inhibiting Lysosomal and Proteasomal Degradation of the Internalized Receptor.
Hatton N, Lintz E, Mahankali M, Henkels KM, Gomez-Cambronero J. Hatton N, et al. Mol Cell Biol. 2015 Sep;35(18):3131-44. doi: 10.1128/MCB.00286-15. Epub 2015 Jun 29. Mol Cell Biol. 2015. PMID: 26124282 Free PMC article. - A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway.
Wei L, Yang Y, Gupta P, Wang A, Zhao M, Zhao Y, Qu M, Ke Y, Liu Y, Liu HM, Xu X, Sun Y, Chen ZS, Hu Z. Wei L, et al. Mol Ther Oncolytics. 2020 Jun 9;18:137-148. doi: 10.1016/j.omto.2020.06.008. eCollection 2020 Sep 25. Mol Ther Oncolytics. 2020. PMID: 32671189 Free PMC article. - Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
Wang LX, Wang JD, Chen JJ, Long B, Liu LL, Tu XX, Luo Y, Hu Y, Lin DJ, Lu G, Long ZJ, Liu Q. Wang LX, et al. Sci Rep. 2016 Nov 8;6:35533. doi: 10.1038/srep35533. Sci Rep. 2016. PMID: 27824120 Free PMC article. - Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.
Pene-Dumitrescu T, Smithgall TE. Pene-Dumitrescu T, et al. J Biol Chem. 2010 Jul 9;285(28):21446-57. doi: 10.1074/jbc.M109.090043. Epub 2010 May 7. J Biol Chem. 2010. PMID: 20452982 Free PMC article. - A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases.
Hayakawa F, Sugimoto K, Harada Y, Hashimoto N, Ohi N, Kurahashi S, Naoe T. Hayakawa F, et al. Blood Cancer J. 2013 Nov 29;3(11):e166. doi: 10.1038/bcj.2013.63. Blood Cancer J. 2013. PMID: 24292418 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous